Delta-type Opioid Receptor 1 (OPRD1) Genotyping
OPRD1 (Delta-type opioid receptor) belongs to the enkephalin receptor family and is coded for by the OPRD1 gene located at 1p35.3. OPRD1 is a G protein-coupled receptor present in the central nervous system that is involved in different neurological processes including pain perception, relaxation, and analgesia. Upon ligand binding, these receptors induce G-protein mediated adenylate cyclase activation and inhibition of neurotransmitter release in the synapse via minimizing calcium ion supply.
OPRD1 receptors interact with endogenous opioid molecules including beta-endorphin, endomorphines, and dynorphines, eliciting downstream signaling. This usually doesn’t occur since the receptors are limited and are not increased unless the genes are altered to produce excessive OPRD1 transcripts or there is increased demand. A number of OPRD1 gene polymorphisms are known to be associated with opioid dependence and abuse. Three variants: rs77585854, rs111622802, and rs118175398 have a higher frequency in South American, African, and Asian ethnicities respectively. Furthermore, variants rs1042114 and rs2234918 are observed in different ethnicities and increase the risk of opioid dependence.
The association between opioid addiction and dependence on OPRD1 variants is attributed to excess production of OPRD1 resulting in interactions with opioids and producing an analgesic effect via rewarding pathways. Furthermore, OPRD1 variants are also linked to affecting the pharmacogenomics of analgesic drugs like methadone and buprenorphine. Variant rs678849 has been found to enhance response to methadone. In contrast, few variants have reported tolerance to the administration of morphine.
- Useful in the investigation of opioid abuse and dependence
- Aids in predicting the response to methadone and morphine
A positive result indicates the presence of the targeted variant(s) in the OPRD1 gene.
- Low risk: Minor allele (T)
- High risk: Major allele (C)
A negative result indicates the absence of the targeted variant(s) in the OPRD1 gene, however, doesn’t rule out potential opioid dependence.
Negative (Normal variant)
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unstable
- Handb Exp Pharmacol. 2018;247:131-145. [PMID: 28035534]
- Transl Psychiatry. 2021 May 25;11(1):316. [PMID: 34031368]
- Am J Drug Alcohol Abuse. 2021 Sep 3;47(5):581-589. [PMID: 34407719]
- Addict Biol. 2014 Jan;19(1):111-21. [PMID: 22500942]